Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.

doi:10.1158/1078-0432.CCR-20-0418

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2020

Park Wungki, Chen Jiapeng, Chou Joanne F, Varghese Anna M, Yu Kenneth H, Wong Winston, Capanu Marinela, Balachandran Vinod, McIntyre Caitlin A, El Dika Imane, Khalil Danny N, Harding James J, Ghalehsari Nima, McKinnell Zoe, Chalasani Sree B, Makarov Vladimir, Selenica Pier, Pei Xin, Lecomte Nicolas, Kelsen David P, Abou-Alfa Ghassan K, Robson Mark E, Zhang Liying, Berger Michael F, Schultz Nikolaus, Chan Timothy A, Powell Simon N, Reis-Filho Jorge S, Iacobuzio-Donahue Christine A, Riaz Nadeem, O'Reilly Eileen M

Abstract excerpt

PURPOSE: Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response-targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome. EXPERIMENTAL DESIGN: We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Genomics

Share to Germ-Line Mutation

Share to Homologous Recombination

Share to Neoplasm Staging

Share to Pancreatic Neoplasms

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 32444418
DOI: 10.1158/1078-0432.CCR-20-0418
PMCID: PMC7380542

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.PMID 32444418Read ↗

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in TaiwanSemantic proximity Read ↗

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future ProspectsSemantic proximity Read ↗

Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancerSemantic proximity Read ↗

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor ProgramSemantic proximity Read ↗

DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectivesSemantic proximity Read ↗

Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomesSemantic proximity Read ↗

Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer PatientsSemantic proximity Read ↗

Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT databaseSemantic proximity Read ↗

Targeting DNA Damage Repair Mechanisms in Pancreas CancerSemantic proximity Read ↗

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for PracticeSemantic proximity Read ↗

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.